BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
6 Internet based Staple Help You Can Trust - 2Creative Do-It-Yourself Ventures for Each Expertise Level
- 3Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- 4Peloton recalls more than 800,000 bikes after broken seat posts injure users
- 5Well known Tea Brands for Each Tea Sweetheart
- 6 Arranging Administrations to Change Your Open air Space
- SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests
- Most loved Road Food: Which One Prevails upon You?
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
- Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
- The Best Competitors of the 21st Hundred years
- Relish the World: Notable Caf\u00e9s You Really want to Attempt
